# US 2020/0129509 A1 · Dosing regimen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0129509 A1
- Document ID: US20200129509A1
- Status: Published application
- Kind: A1
- Application number: 16/171,719
- Filed: 2018-10-26
- Published: 2020-04-30
- Earliest claimed: 2018-10-26
- Assignees: Cyclacel Limited
- Applicants: Cyclacel Limited
- Inventors: Judy H. CHIAO
- Web page: https://patentgrep.com/patent/US20200129509A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/02: Inorganic compounds
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a method of treating AML in a subject having a white blood cell (WBC) count of less than about 10,000 cells/microliter, and/or a cytogenetic risk classification according to the US Southwest Oncology Group (SWOG) that is not unfavourable, and/or the subject falls within a classification selected from antecedent myelodysplastic syndrome (MDS), antecedent myeloproliferative neoplasm (MPN), and antecedent myelodysplastic/myeloproliferative neoplasm (MDS/MPN), wherein the method comprises (i) a first treatment cycle comprising administering decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and (ii) a second treatment cycle comprising administering sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.

## Claims

### Claim 1

A method of treating AML in a subject, wherein said subject:
(I) has a white blood cell (WBC) count of less than about 10,000 cells/microliter, and/or
(II) has a cytogenetic risk classification according to the US Southwest Oncology Group (SWOG) that is not unfavourable, and/or
(III) falls within a classification selected from antecedent myelodysplastic syndrome (MDS), antecedent myeloproliferative neoplasm (MPN), and antecedent myelodysplastic/myeloproliferative neoplasm (MDS/MPN);
said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle,
wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and
wherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the second treatment cycle comprises administering a therapeutically effective amount of sapacitabine.

### Claim 3 (depends on 1)

A method according to claim 1 wherein the metabolite of sapacitabine is CNDAC.

### Claim 4 (depends on 1)

A method according to claim 1 wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer.

### Claim 5 (depends on 1)

A method according to claim 1 wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 consecutive days followed by a 3 week rest period.

### Claim 6 (depends on 1)

A method according to claim 1 wherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine or metabolite thereof for 3 consecutive days per week, for 2 weeks followed by a 2 week rest period

### Claim 7 (depends on 1)

A method according to claim 1 which comprises two or more of each treatment cycle.

### Claim 8 (depends on 1)

A method according to claim 1 which comprises two to four of each treatment cycle.

### Claim 9 (depends on 1)

A method according to claim 1 wherein the decitabine is administered intravenously.

### Claim 10 (depends on 1)

A method according to claim 1 wherein the decitabine is administered in a dose of from about 10 to about 20 mg/m2.

### Claim 11 (depends on 1)

A method according to claim 1 wherein the decitabine is administered in a dose of about 20 mg/m2 per day.

### Claim 12 (depends on 1)

A method according to claim 1 wherein the decitabine is administered by intravenous infusion over a period of about 1 hour.

### Claim 13 (depends on 1)

A method according to claim 1 wherein the sapacitabine or metabolite thereof is administered orally.

### Claim 14 (depends on 13)

A method according to claim 13 wherein the sapacitabine or metabolite thereof is administered in a dose of about 100-400 mg b.i.d., more preferably from about 250-300 mg b.i.d.

### Claim 15 (depends on 14)

A method according to claim 14 wherein the sapacitabine or metabolite thereof is administered in a dose of about 300 mg b.i.d.

### Claim 16 (depends on 1)

A method according to claim 1 wherein the subject is an elderly subject.

### Claim 17 (depends on 16)

A method according to claim 16 wherein the subject is 70 years of age or over.

### Claim 18

A method of treating AML in an elderly subject, wherein said subject:
(I) has a white blood cell (WBC) count of less than about 10,000 cells/microliter and/or
(II) has a cytogenetic risk classification according to the US Southwest Oncology Group (SWOG) that is not unfavourable, and/or
(III) falls within a classification selected from antecedent myelodysplastic syndrome (MDS), antecedent myeloproliferative neoplasm (MPN), and antecedent myelodysplastic/myeloproliferative neoplasm (MDS/MPN);
said method comprising administering to a subject a therapeutically effective amount of (i) sapacitabine; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle,
wherein said first treatment cycle comprises administering decitabine intravenously in a dose of about 20 mg/m2per day for 5 to 10 consecutive days followed by a 3 to 5 week rest period, or until treatment-related toxicities are resolved, whichever is longer; and
wherein said second treatment cycle comprises administering sapacitabine orally in a dose of about 300 mg b.i.d. for 3 consecutive days per week, for 2 weeks followed by a 2 to 4 week rest period, or until treatment-related toxicities are resolved, whichever is longer.

### Claim at position 19

19-28. (canceled)

### Claim 29

A kit of parts comprising:
(i) sapacitabine, or a metabolite thereof;
(ii) decitabine; and
(iii) instructions for administering sapacitabine, or a metabolite thereof, and decitabine to a subject, in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said subject:
(I) has a white blood cell (WBC) count of less than about 10,000 cells/microliter and/or
(II) has a cytogenetic risk classification according to the US Southwest Oncology Group (SWOG) that is not unfavourable, and/or
(III) falls within a classification selected from antecedent myelodysplastic syndrome (MDS), antecedent myeloproliferative neoplasm (MPN), and antecedent myelodysplastic/myeloproliferative neoplasm (MDS/MPN);
wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and
wherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.

### Claim 30 (depends on 29)

The kit of parts according to claim 29,
wherein said first treatment cycle comprises administering decitabine intravenously in a dose of about 20 mg/m2 for 5 to 10 consecutive days followed by a 3 to 5 week rest period, or until treatment-related toxicities are resolved, whichever is longer; and
wherein said second treatment cycle comprises administering sapacitabine orally in a dose of about 300 mg b.i.d. for 3 consecutive days per week, for 2 weeks followed by a 2 to 4 week rest period, or until treatment-related toxicities are resolved, whichever is longer.

### Claim at position 22

31-32. (canceled)
